<DOC>
	<DOC>NCT00333047</DOC>
	<brief_summary>Therapeutic interventions for patients with metastatic breast cancer are aimed at prolonging survival and improving the quality of life. The objective of this trial is to assess if an initial chemotherapy followed by an endocrine therapy leads to a longer disease-free interval as compared to chemotherapy alone.</brief_summary>
	<brief_title>Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criteria Histologically proven metastatic breast cancer Measurable disease, patients with bone only disease are not eligible Age ≥ 65 years Performance status ≤ 2 (World Health Organization) Estimated life expectancy under therapy of at least 3 months Estrogen/progesteronereceptor status positive or unknown Signed informed consent Exclusion criteria Prior chemo or hormone therapy for metastatic breast cancer; prior therapy with aromatase inhibitors in the adjuvant setting Diseasefree interval after adjuvant therapy &lt; 1 year Clinical signs of central nervous system metastases Renal, bone marrow, or liver insufficiency Severe coronary heart disease, cardiac insufficiency or other severe concomitant internal diseases Pulmonary fibrosis/alveolitis Additional protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Letrozole</keyword>
</DOC>